A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
A study on subjects with systemic lupus erythematosus using study drug CC-220
Sponsor: Celgene
Enrolling: Male and Female Patients
Study Length: 28 Weeks
IRB Number: AAAN9104
U.S. Govt. ID: NCT02185040
Contact: Anca Askanase: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: This study is for patients who have been diagnosed with systemic Lupus erythematosus (SLE). SLE is a disease in which the body mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain and other organs. The purpose of this study is to test the effects of an investigational (being tested) study drug, CC 220, in order to find out if CC-220 can or cannot improve the symptoms of SLE. This study will test two different doses of CC-220 compared to placebo. The placebo is a sugar pill that contains no study medication (or CC-220), but looks exactly like the study medication capsule. This study will test how well the body tolerates CC-220 and how well CC-220 treats SLE.
This study is closed
Anca Askanase, MD, MPH
Do You Qualify?
Have you been diagnosed with lupus for at least 6 months? Yes No
Do you have a history of an organ transplant or hematopoietic stem cell/ marrow transplant? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Anca Askanase